Pre-earnings brief
Reports
Wed, Aug 5, 2026
Est. EPS
$0.74
Est. revenue
$155M
Implied move
±5.0%
EPS beat rate
100%
Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. With a market cap of $4 billion, its work is crucial in addressing unmet medical needs in the healthcare sector.
Last quarter
In Q1-2026, Catalyst Pharmaceuticals reported an EPS of $0.79, significantly beating expectations of $0.58, showcasing strong performance. However, revenue details were not disclosed, leaving some uncertainty.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+36.69%
Avg 1-day reaction
+0.67%
Analysts expect Catalyst Pharmaceuticals to report solid earnings this quarter, with a consensus EPS of $0.74 and revenue of $155 million. Given the company's history of beating EPS estimates, there is cautious optimism.
Bull case
If the company exceeds the EPS and revenue estimates, it could signal strong demand for its products and effective management strategies, potentially boosting investor confidence.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects and lead to a negative market reaction.
Key metrics to watch
Earnings Per Share (EPS)
$0.74EPS is a key indicator of the company's profitability and financial health, and investors will look for any surprises compared to expectations.
Revenue
$155MRevenue reflects the company's ability to generate sales, which is vital for growth and sustainability in the competitive biotech industry.
The print will turn on these.
Q1
Will the EPS exceed $0.74 as expected?
A beat on EPS would reinforce the company's strong performance trend and could lead to a positive stock reaction.
Q2
What guidance will management provide regarding future revenue growth?
Future revenue guidance will be critical for assessing the company's growth trajectory and market confidence.
Why consensus could be wrong
The Street may underestimate the potential for revenue growth driven by new product launches, which could significantly outperform current expectations.
Supporting evidence
The company has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.
Historical data shows that the stock has reacted positively to strong earnings surprises, suggesting potential for upside.
The lack of recent insider activity may indicate confidence in the company's future performance.
Key risk
If revenue growth significantly exceeds $155 million, it could challenge the current market consensus.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will either validate the company's growth strategy or highlight potential weaknesses.
Bull confirmed if
An EPS of $0.80 or higher, coupled with revenue exceeding $160 million, would confirm strong operational performance.
Bear confirmed if
An EPS below $0.70 or revenue falling short of $150 million would raise concerns about the company's growth outlook.
What the market is pricing for the move.
Implied Move
±5%
Historical Avg
±1.4%
The options market is pricing in a 5% potential move in either direction following the earnings report, indicating uncertainty among investors.
Options are pricing ±5.0% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.
30d HV
1.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Catalyst beats expectations, history suggests a potential average one-day move of +0.67%, confirming the bullish sentiment.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future guidance.
Miss
A miss could lead to a decline, with historical patterns suggesting an average one-day move of -1.94%.
The lines on the call that would change the story.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%